The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIntertek Group Regulatory News (ITRK)

Share Price Information for Intertek Group (ITRK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 4,888.00
Bid: 4,886.00
Ask: 4,890.00
Change: -24.00 (-0.49%)
Spread: 4.00 (0.082%)
Open: 4,906.00
High: 4,910.00
Low: 4,888.00
Prev. Close: 4,912.00
ITRK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Acquisition

19 Feb 2008 07:00

Intertek Group PLC19 February 2008 Intertek acquires CML Biotech Limited Intertek Group plc (Intertek), the leading international provider of quality andsafety services to a wide range of industries, announces the acquisition of CMLBiotech Limited (CML), the holding company for the Commercial MicrobiologyGroup, a microbiology testing laboratory and consulting business for the oil andgas industry. Intertek purchased CML from its management shareholders Dr Stephen Maxwell andJohn McCulloch for an initial cash consideration of GBP 8 million and deferredconsideration of approximately GBP 2 million payable in March 2009. CML provides laboratory and consultancy services and sells testing kitsrelated to the measurement and management of bacteria in the upstream oil andgas industry. The business supports oil and gas exploration companies inaddressing bacterial contamination of pipelines and infrastructure used duringproduction, storage, and extraction of oil and gas reserves. The integrity ofpipelines is affected by corrosion caused by bacteria. Bacterial and hygieneservices are also provided for drinking water supplied to offshore platforms and vessels. CML has a strong industry wide reputation for its expertise andexperience in this analytical services sector. While the majority of CML's operations are in the North Sea and Gulf of Mexicomarkets, CML also supports the other main oil and gas provinces, including Northand West Coast Africa, the Caspian Sea and the Middle East. These and other oilreserve regions present growth opportunities for CML and Intertek together. CML has 54 employees in total, based in Aberdeen, Scotland and in Houston, USA,and it will form part of Intertek's Analytical Services division. Wolfhart Hauser, Chief Executive Officer of Intertek, commented:"CML is a valuable addition to our upstream analytical services business. Thebusiness holds a very strong and impressive market position in microbialservices, which will expand the suite of expert services that we deliver as apartner to the oil & gas exploration industry globally". -ends-ContactsAston Swift / Sarah Ogilvie IntertekTelephone: +44 (0) 20 7396 3400aston.swift@intertek.com / sarah.ogilvie@intertek.com Richard Mountain / Sophie Kernon, Financial DynamicsTelephone: +44 (0) 20 7269 7121richard.mountain@fd.com / sophie.kernon@fd.com Notes to Editors From 1 January 2008, Intertek's Analytical Services, previously part of theGroup's Oil Chemical & Agri division, became a standalone division. For furtherdetails of this and the surrounding divisional re-organisation, refer toIntertek's stock exchange announcement of 11 December 2007. ABOUT INTERTEK Intertek (LSE: ITRK) is the leading international provider of quality and safetyservices to a wide range of global and local industries. Partnership withIntertek brings increased value to customers' products and processes, ultimatelysupporting their success in the global market place. Intertek has theexperience, expertise, resources and global reach to support its customersthrough itsextensive network of laboratories and offices, with over 20,000 people in morethan 100 countries around the world.www.intertek.com This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
22nd Mar 20249:00 amRNSAnnual Financial Report
14th Mar 20241:00 pmRNSDirector/PDMR Shareholding
14th Mar 20241:00 pmRNSDirector/PDMR Shareholding
13th Mar 20241:00 pmRNSDirector/PDMR Shareholding
5th Mar 20247:00 amRNSFinal Results
4th Mar 20247:00 amRNSAcquisition
1st Mar 20241:00 pmRNSDirectorate Change
28th Feb 20241:00 pmRNSDirector/PDMR Shareholding
23rd Nov 20237:00 amRNSTrading Statement
22nd Nov 20231:00 pmRNSBlock listing Interim Review
14th Sep 20231:00 pmRNSDirector Declaration
24th Aug 20237:00 amRNSAcquisition
28th Jul 20237:00 amRNSHalf-year Report
12th Jul 202310:00 amRNSDirectorate Change
7th Jun 20231:00 pmRNSDirector/PDMR Shareholding
31st May 20231:00 pmRNSDirector/PDMR Shareholding
30th May 20233:00 pmRNSHolding(s) in Company
30th May 20231:00 pmRNSBlock listing Interim Review
24th May 202311:00 amRNSResult of AGM
24th May 20237:00 amRNSTrading Statement
3rd May 20237:00 amRNSCapital Markets Event
27th Apr 20234:00 pmRNSDirector Declaration
26th Apr 20234:30 pmRNSDirector Declaration
20th Apr 20234:00 pmRNSDirector Declaration
3rd Apr 20237:00 amRNSAcquisition
24th Mar 20239:00 amRNSNotice of 2023 AGM
21st Mar 20239:00 amRNSAnnual Financial Report
20th Mar 20237:00 amRNSDirectorate Change
14th Mar 20233:00 pmRNSDirector/PDMR Shareholding
14th Mar 20233:00 pmRNSDirector/PDMR Shareholding
14th Mar 20233:00 pmRNSDirector/PDMR Shareholding
28th Feb 20237:00 amRNSFinal Results
23rd Dec 202210:00 amRNSDirectorate Change
13th Dec 202211:00 amRNSDirector Declaration
12th Dec 20221:00 pmRNSDirector Declaration
24th Nov 20227:00 amRNSTrading Statement
21st Nov 20221:00 pmRNSBlock listing Interim Review
2nd Aug 20229:00 amRNSDirector/PDMR Shareholding
29th Jul 20227:01 amRNSAcquisition
29th Jul 20227:00 amRNSHalf-year Report
21st Jun 20221:00 pmRNSDirector/PDMR Shareholding
26th May 20227:00 amRNSDirectorate Change
25th May 202211:00 amRNSResult of AGM
25th May 20227:00 amRNSTrading Statement
23rd May 20221:00 pmRNSBlock listing Interim Review
4th Apr 20223:00 pmRNSDirector/PDMR Shareholding
22nd Mar 20221:00 pmRNSDirector/PDMR Shareholding
22nd Mar 20221:00 pmRNSDirector/PDMR Shareholding
18th Mar 20229:00 amRNSAnnual Financial Report
14th Mar 20221:00 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.